The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.

BMC Cancer · 2011 · PMC3162585 · PMID 21827707

Europe PMC DOI

hedged sentence

0.0690

closest p · 1.4× alpha

0.0690

boldest claim

The sentences

did not reach statistical significanceP = 0.069so close (0.05 < p ≤ 0.1)

Regarding MSI, patients with MSI-high CRCs showed longer RFS than those with MSI-low or MSS CRCs, although this difference did not reach statistical significance (three-year RFS: 90.6% vs. 79.2%; P = 0.069).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.